Veracyte Inc. Aktie
Deine Einschätzung
Veracyte Inc. Aktie
Was spricht für und gegen Veracyte Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Veracyte Inc. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Veracyte Inc. | -2,16 % | -6,05 % | -7,11 % | 129,18 % | 32,42 % | 92,22 % | 30,25 % |
| Evolus Inc | -0,04 % | -0,50 % | -14,13 % | -33,15 % | -4,33 % | -42,70 % | -41,08 % |
| Heron Therapeutics Inc. | -1,99 % | 2,96 % | 15,56 % | -71,51 % | -61,33 % | -69,23 % | -95,85 % |
| Rhythm Pharmaceuticals | -1,08 % | 1,67 % | -5,18 % | 26,21 % | -2,14 % | 479,11 % | 535,42 % |
Kommentare
News
A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.
Jonathan Wygant, Vice President and Chief Accounting Officer of Veracyte (NASDAQ:VCYT), reported the exercise of 24,000 options and immediate open-market sale of the same number of shares for a
What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock Rally
Karin Eastham, a director of Veracyte (NASDAQ:VCYT), reported the sale of 3,729 shares of common stock in multiple open-market transactions on June 18, 2026, as detailed in the SEC Form 4 filing.
Why Veracyte Stock Is Skyrocketing Higher This Week
Shares of leading diagnostics platform and cancer-detecting genomic test provider Veracyte (NASDAQ: VCYT) are up 23% over the last week as of market close Thursday, after the company reported




